# Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects

> **NCT05249374** · PHASE1 · COMPLETED · sponsor: **Protgen Ltd** · enrollment: 36 (actual)

## Conditions studied

- Hepatic Ascites

## Interventions

- **DRUG:** Recombinant Human Serum Albumin
- **DRUG:** Human serum albumin

## Key facts

- **NCT ID:** NCT05249374
- **Lead sponsor:** Protgen Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-14
- **Primary completion:** 2022-05-16
- **Final completion:** 2022-05-16
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05249374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05249374, "Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05249374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*